Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St. Jude Persists In Effort To Correct The Record On Riata Study

This article was originally published in The Gray Sheet

Executive Summary

“We will continue to work through the proper channels with the HeartRhythm journal and the Heart Rhythm Society to ensure there is an appropriate presentation of validated, accurate information,” a company spokeswoman said.

You may also be interested in...

St. Jude Durata ICD Lead Insulation Breaches Probed In Hauser Study

MAUDE analysis suggests some trouble spots for St. Jude’s newer Optim-insulated ICD leads, according to researchers. But the company says the overall data shows the products to be as safe and reliable as competitors’ offerings.

Research In Brief

St. Jude Medical reports updated Riata defibrillator lead data. Alzheimer’s RNA-based blood test studies make progress. More research news.

Medical Device Market & Industry Briefs, April 2012

Brief summaries of recent medtech market and industry developments. This month we cover Covidien’s continuing buying spree, and other medtech M&A.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts